CD274 and gastric cancer: A Phase 3 trial of pembrolizumab indicated that PD-L1 CPS may be superior to PD-L1 TPS as a predictive biomarker of response to pembrolizumab in patients with GC.10 Mishima et al. reported that PD-L1 TPS ≥ 1, but not PD-L1 CPS ≥ 10, was significantly associated with response,17 which was contrary to our results.